Davis / Herbst / Abbruzzese Antiangiogenic Cancer Therapy

Erscheinungsjahr 2010
ISBN: 978-1-4200-0429-8
Verlag: Taylor & Francis
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 864 Seiten

Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. - Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.

- Covers specific molecular targets for inhibiting angiogenesis in cancer therapy.

- Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors.

- Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.
This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.

Zielgruppe

Clinical trial leaders and decision makers (industry), researchers, clinicians, oncologists, pharmaceutical scientists, pharmacologists, and graduate students in these areas<s> </s>

Autoren/Hrsg.

Davis, Darren W.

Herbst, Roy S.

Abbruzzese, James L.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin

Inhaltsverzeichnis

Table of Contents

PART I. ANGIOGENESIS IN CANCER

Strategies to Prolong the Nonangiogenic Dormant State of Human Cancer; George N. Naumov and Judah Folkman

Vascular Endothelial Growth Factor: Basic Biology and Clinical Implications; Napoleone Ferrara

Angiogenesis in Solid Tumors; Rakesh K. Jain and Dan G. Duda

Pathophysiologic Role of VEGF in Hematologic Malignancies; Klaus Podar, Shaji Kumar, Dharminder Chauhan, and Kenneth C. Anderson

Tumor Microenvironment and Angiogenesis; Cheryl H. Baker and Isaiah J. Fidler

PART II. TARGETING ANGIOGENESIS FOR CANCER THERAPY

Tyrosine Kinase Inhibitors of Angiogenesis; Janessa J. Laskin and Alan B. Sandler

Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy; Zhenping Zhu and Daniel J. Hicklin

Targeting Fibroblast Growth Factor/Fibroblast Growth Factor Receptor System in Angiogenesis; Marco Rusnati and Marco Presta

Development of the VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and Discovery of the Next Generation of Angiogenesis Targets; John S. Rudge, Gavin Thurston, Samuel Davis, Nicholas Papadopoulos, Nicholas W. Gale, Stanley J. Wiegand, and George D. Yancopoulos

Proteinases and Their Inhibitors in Angiogenesis; Yves A. DeClerck, Khalid Bajou, and Walter E. Laug

Prostaglandins and COX-2: Role in Antiangiogenic Therapy; Kristin Hennenfent, Daniel Morgensztern, and Ramaswamy Govindan

Integrins, Adhesion, and Coadhesion Inhibitors in Angiogenesis; Abebe Akalu and Peter C. Brooks

Conventional Therapeutics with Antiangiogenic Activity; Christian Hafner, Thomas Vogt, and Albrecht Reichle

Vascular Disrupting Agents; David J. Chaplin, Graeme J. Dougherty, and Dietmar W. Siemann

Vascular and Hematopoietic Stem Cells as Targets for Antiangiogenic Therapy; Shahin Rafii

Genetic Strategies for Targeting Angiogenesis; Anita Tandle, Mijung Kwon, and Steven K. Libutti

Identification of New Targets Using Expression Profiles; Thomas R. Burkard, Zlatko Trajanoski, Maria Novatchkova, Hubert Hackl, and Frank Eisenhaber

PART III. TRANSLATING ANGIOGENESIS INHIBITORS TO THE CLINIC

Clinical Trial Design and Regulatory Issues; Ramzi N. Dagher and Richard Pazdur

Surrogate Markers for Antiangiogenic Cancer Therapy; Darren W. Davis

Noninvasive Surrogates; Bruno Morgan and Mark A. Horsfield

Pharmacodynamic Markers in Tissues; Darren W. Davis

Blood-Based Biomarkers for VEGF Inhibitors; Amado J. Zurita, Hua-Kang Wu, and John V. Heymach

PART IV. TREATMENT OF SPECIFIC CANCERS WITH ANGIOGENESIS INHIBITORS

Antiangiogenic Therapy for Colorectal Cancer; Paulo M. Hoff and Everardo D. Saad

Combined Modality Therapy of Rectal Cancer; Christopher G. Willett and Dan G. Duda

Antiangiogenic Therapy for Breast Cancer; Pablo M. Bedano, Brian P. Schneider, Kathy D. Miller, and George W. Sledge Jr.

Antiangiogenic Therapy for Lung Malignancies; David J. Stewart

Antiangiogenic Therapy for Prostate Cancer; Leslie K. Walker, Glenn Liu, and George Wilding

Antiangiogenic Therapy for Hematologic Malignancies; Karen W.L. Yee and Francis J. Giles

Antiangiogenic Therapy for Gliomas; Heinrich Elinzano and Howard A. Fine

Antiangiogenic Therapy for Kaposi’s Sarcoma; Henry B. Koon, Liron Pantanowitz, and Bruce J. Dezube

Antiangiogenic Therapy for Melanoma; Keith Dredge and Angus G. Dalgleish

Sunitinib and Renal Cell Carcinoma; Robert J. Motzer and Sakina Hoosen

Index